

1 Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and
2 Denmark.

3 Short title: Exposure to valsartan products with nitrosamine impurities

4 Efe Eworuke, PhD,¹ Mayura U. Shinde,² Laura Hou,² J. Michael Paterson, MSc³ Peter Bjødstrup
5 Jensen, PhD,⁴ Judith C. Maro, PhD,² Ashish Rai, PhD, MSPH, MBBS² Anton Pottegård, PhD⁴
6 Daniel Scarnecchia, MPIA² Yuanling Liang, PhD¹, Deborah Johnson, PhD,¹ Robert W. Platt,
7 PhD³, Hana Lee, PhD¹ Marie C. Bradley, PhD, MPharm, MSc.PH¹

8 Author Affiliations:

- 9 1. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring,
10 MD, USA
- 11 2. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
12 Health Care Institute, Boston, MA, USA
- 13 3. Canadian Network for Observational Drug Effect Studies (CNODES), Montréal, QC, CA
- 14 4. University of Southern Denmark, Odense, DK

15 Corresponding author: Marie C. Bradley

16 Division of Epidemiology II, Center for Drug Evaluation and Research, U.S. Food and Drug
17 Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993

18 Telephone: 240-402-9985

19 Fax: 301-796-9850

20 Email: marie.bradley@fda.hhs.gov

21 Abstract word count: 341

22 Manuscript word count: 2267

23 Disclaimer: The views expressed in this publication are those of the authors and should not be

24 construed to represent the official policy or views of the US Food and Drug Administration or

25 Health Canada.

26 **ABSTRACT**

27 Background: Following the mass recall of valsartan products with nitrosamine impurities in July
28 2018, the number of patients exposed to these valsartan products, the duration of exposure, and
29 the potential for cancer remains unknown. Therefore, we assessed the extent and duration of use
30 of valsartan products with a nitrosamine impurity in the US, Canada, and Denmark.

31 Methods: We conducted a retrospective cohort study using administrative healthcare data from
32 the US FDA Sentinel System, four Canadian provinces that contribute to the Canadian Network
33 for Observational Drug Effect Studies (CNODES), and the Danish National Prescription
34 Registry. Patients, 18 years and older between May 2012 and December 2020 with a valsartan
35 dispensing were identified in each database. Patients were followed from the date of valsartan
36 dispensing until discontinuation. We defined four valsartan exposure categories based on
37 nitrosamine impurity status; recalled generic products with confirmed NDMA/NDEA levels
38 (recalled-tested); recalled generic products that were not tested (recalled); non-recalled generic
39 and non-recalled branded products. In Denmark, recalled-tested category was not included due to
40 absence of testing data. The proportion and duration of use of valsartan episodes stratified by
41 nitrosamine-impurity status.

42 Results: We identified 3.3 and 2.8 million (US) and 51.3 and 229 thousand (Canada) recalled-
43 tested and recalled valsartan exposures. In Denmark, where valsartan exposure was generally
44 low, there were 10,747 recalled exposures. Immediately after the recall notices were issued, there
45 was increased rates of switching to a non-valsartan ARB. The mean duration of use of the
46 recalled-tested products was 167(\pm 223.1) and 146(\pm 255.8) days in the US and Canada
47 respectively. For the recalled products, mean cumulative duration of use was 178(\pm 249.6),
48 269(\pm 397.3) and 166(\pm 251.0) days in the US, Canada, and Denmark, respectively.

49 Conclusion: In this cohort study, despite widespread use of recalled generic valsartan between
50 2012 and 2018, the duration of use was relatively short and likely did not pose an elevated risk of
51 nitrosamine-induced cancer. However, since products with nitrosamine impurity could have been
52 on the market over a six-year period, patients potentially exposed to these products for longer
53 duration could have a different risk of cancer.

54

55 INTRODUCTION

56 The mass recall of valsartan products with nitrosamine impurities in July 2018 prompted a series
57 of investigations into the etiology and level of nitrosamine impurities, and the potential for
58 cancer risk. Regulatory agencies quickly learned that the presence of N-nitrosodimethylamine
59 (NDMA) and N-nitroso-diethylamine (NDEA) impurities in some valsartan products occurred as
60 far back as 2012¹⁻⁵ due to a change in manufacturing processes. Our previous study⁶ investigated
61 trends in valsartan and other ARB use and found that the first recall notice for valsartan resulted
62 in substantial decline in use due to increased switching to other ARBs. However, the extent of
63 exposure to valsartan products with nitrosamine impurities before the recall, and the associated
64 potential cancer risk remains unknown. In October 2018, regulatory agencies published test
65 results showing NDMA levels in recalled valsartan products exceeded safe levels.^{6,7} The results
66 were subsequently updated in February 2019 with the NDEA levels. For reference, consuming
67 up to 0.096 micrograms (mcg) of NDMA or 0.0265 mcg of NDEA per day is considered
68 reasonably safe for human ingestion based on lifetime exposure. The highest NDMA levels were
69 between 14 and 20 mcg, while the highest NDEA levels were between 1.1 and 1.3mcg. Since
70 cancer risk is dependent on both dose and years of exposure, it was determined that if 8,000
71 patients took the maximum recommended daily dose (320mg daily) of valsartan containing
72 NDMA at levels of 96 ng/day (0.096 mcg) and 18,000 people took the highest dose of valsartan
73 containing NDEA at levels of 26.5 ng/day (or 0.0265 mcg/day) for four years, there may be only
74 one additional cancer case.⁷ This study examined the extent and duration of use of valsartan
75 products with nitrosamine impurities and estimated the potential for cancer based on the
76 observed duration of use of these products in the US, Canada, and Denmark.

78 **METHODS**

79 A retrospective cohort study was conducted between January 1, 2012, through December 31,
80 2020, using data from six data partners that contribute data to the US FDA Sentinel System, data
81 from four Canadian provinces that contribute to the Canadian Network for Observational Drug
82 Effect Studies (CNODES), and the Danish National Prescription Registry. The FDA's Sentinel
83 system includes data on medical encounters (inpatient and outpatient diagnoses and procedures)
84 and outpatient pharmacy claims data (retail and mail order filled prescriptions) accrued during
85 health plan enrollment periods. These data are routinely quality-assured and transformed into the
86 Sentinel Common Data Model to facilitate queries.¹² Additional descriptions of data sources are
87 provided in Supplement A.

88 We included patients aged 18 years and older with at least one valsartan dispensing during the
89 study period, between January 2012 to December 2020 for US and Canada and January 2012 to
90 May 2020 for Denmark. Four valsartan exposure categories were defined based on valsartan
91 impurity status; recalled products with a laboratory test result confirming the presence of
92 NDMA/NDEA based on FDA and Health Canada analyses (recalled-tested); recalled products
93 that were not tested (recalled); non-recalled generic and non-recalled branded valsartan-
94 containing products (Diovan, Entresto, Exforge and Sandoz-Valsartan). In Denmark, we did not
95 have access to NDMA/NDEA testing data, hence valsartan products were categorized into
96 recalled, non-recalled generic and non-recalled branded categories. The algorithms for exposure
97 definitions are presented in supplement B. Valsartan exposure episodes were created by
98 summing the number of days dispensed with a gap of 30 days or less for the respective exposure
99 category. Patients were followed until they discontinued the product, switched to another
100 valsartan exposure category or a different angiotensin receptor blocker (ARB), disenrollment,

101 death, or study end date. We calculated the proportion of valsartan episodes as the number of
102 valsartan episodes in each exposure category divided by the total valsartan episodes each quarter
103 per year. We also calculated the rate of switching, defined as the number of valsartan episodes
104 for each exposure category that ended in a switch, divided by the total valsartan episodes each
105 quarter per year. Lastly, we estimated the length of episode duration by calculating mean,
106 median and quartiles (lowest and highest median, 25th and 75th percentile recorded across the
107 data partners) between May 2012 and December 2018 (period when we assumed valsartan
108 products with NDMA/NDEA impurity were on the market) for each recall category. All source
109 data were transformed into the Sentinel common data model¹¹, and analyzed using Sentinel's
110 Query Request Program v10.1.1 with custom coding, allowing for the deployment of a common
111 analytical program in all countries.

112 This study conducted in the FDA's Sentinel System is a public health surveillance activity
113 conducted under the authority of the FDA and, accordingly, is not subject to Institutional Review
114 Board oversight.⁹⁻¹¹ This study followed the Strengthening the Reporting of Observational
115 Studies in Epidemiology ([STROBE](#)) reporting guideline.

116

117 **RESULTS**

118 During the study period (May 2012-December 2020), we identified 7,925,941; 442,189 and
119 16,260 valsartan episodes in US, Canada, and Denmark. The distribution of valsartan use by
120 exposure category during the study period for all three countries is presented in Table 1.
121 Exposure to both recalled-tested and recalled products was extensive in the US and Canada. We
122 identified 3.3 (41.6%) and 2.8 (35.7%) million recalled-tested and recalled valsartan exposure
123 episodes in the US and 51,315 (11.6%) and 291,229 (65.9%) recalled-tested and recalled
124 episodes were identified in the Canadian database. In Denmark, the proportion of recalled
125 valsartan exposure was high; 10,747 (66.1%) recalled episodes were identified. Exposure to non-
126 recalled generic and non-recalled branded valsartan products was comparable to the exposure to
127 the recalled products, for all three countries. Around 3.3 (41.5%) and 3.2 (40%) million non-
128 recalled generic and branded episodes, respectively, were identified in Sentinel, while 35,978
129 (8.1%) and 215,999 (48.8%) episodes for non-recalled generic and branded were identified in the
130 Canadian data. In Denmark, 9,395 (57.8%) and 7,632 (46.9%) non-recalled generic and branded
131 valsartan episodes were identified (Table 1).

132 **Trends in valsartan use**

133 The trends in valsartan use, stratified by valsartan impurity status for US, Canada and Denmark
134 are presented in Figures 1-3.

135 *US*

136 In the US, between 2012 and 2015, we observed a steady decline in use of valsartan branded
137 episodes, along with a corresponding increase in the share of the generic (recalled-tested,
138 recalled and non-recalled) products (Figure 1). Recalled-tested products had the largest share of

139 the generic valsartan market in 2012; however, between 2014 and 2015, both non-recalled and
140 recalled products equally shared the valsartan market (Figure 1). Between the third calendar
141 quarter (Q3: July-September) of 2016 and Q3-2018, recalled-tested valsartan products had the
142 largest market share of valsartan products, followed by the recalled products. From Q3 to Q4
143 (October-December) 2018, we observed a steep drop (from 46.0% to 13.9%) in the proportion of
144 recalled-tested valsartan products. The decline in use of recalled products started from Q1
145 (January-March) 2019.

146 *Canada*

147 In Canada, recalled products were the most dispensed valsartan products, followed by non-
148 recalled branded products (Figure 2). Between Q3- and Q4-2018, there was a steep drop in the
149 proportion of recalled products (from 90% in Q2 (April-May) 2018 to 2.6% in Q4-2018); while
150 the trends for non-recalled branded products remained unaffected. Use of recalled-tested and
151 non-recalled generic products was low during the study period.

152 *Denmark*

153 In Denmark, recalled products were the most dispensed valsartan products (Figure 3). Decline in
154 the use of these products beginning in 2017 coincided with the steady increase in non-recalled
155 branded products. When the recall notice was issued (Q3-2018), there was a steep decline from
156 41% (Q3-2018) to 13% (Q4-2018) in recalled products, whereas the proportion of non-recalled
157 branded products increased from 49% to 56% around the same time.

158 **Duration of valsartan episodes**

159 The duration of valsartan exposure episodes, stratified by valsartan-impurity status for the three
160 countries, is presented in Table 2. The mean duration of use of the recalled-tested products was

161 166.9(\pm 223.1) and 145.5(\pm 255.8) days in the US and Canada. The 75th percentile ranged from
162 60-222 days for US and 139-192 days for Canada. For the recalled products, mean duration of
163 use was 178.3(\pm 249.6), 269.0(\pm 397.3) and 166(\pm 251.0) days for US, Canada, and Denmark. The
164 75th percentile range was 60-230, 315-407 and 181 days for US, Canada, and Denmark. The
165 mean duration of use for the non-recalled generic products appeared comparable to mean
166 duration for recalled-tested (US, Canada) and recalled products (Denmark). In Canada (319.2
167 (\pm 489.1)) and Denmark (321.6(\pm 376.2) days), the mean duration of use of the non-recalled
168 branded products was much longer compared to the duration of use in the US (167.7(\pm 228.0)
169 days).

170 **Valsartan switching patterns.**

171 In US and Canada, we observed relatively stable switching patterns for both recalled-tested and
172 recalled products prior to Q2-2018 (Supplemental Figures 1 and 3). In Q2-2018, there was an
173 immediate increase in the switching between valsartan exposure categories and to a non-
174 valsartan ARB. In Denmark, a similar increase in switching was also observed in Q2-2018;
175 however, there was frequent switching from recalled products to non-recalled valsartan products
176 (Supplemental Figure 5). Interestingly, in Q2-2018, there was increased switching from non-
177 recalled valsartan products to a non-valsartan ARB in the US and Canada (Supplemental Figures
178 2 and 4). In Canada, switching from branded valsartan to a non-valsartan ARB increased in Q2-
179 2018 (Supplemental Figure 4), but this trend was not observed in the other countries. In
180 Denmark, switching from the non-recalled generic and branded products to recalled products
181 prior to Q2-2018 was frequent. After Q2-2018, switching rates diminished.

182

183 **DISCUSSION**

184 Our findings suggest that many patients received valsartan products with nitrosamine impurities,
185 at the time when there was no knowledge of the nitrosamine impurities. In all three countries,
186 recalled-tested and recalled valsartan products had the largest share of the valsartan market.
187 Despite widespread use of the products with nitrosamine impurities, duration of use was
188 typically very short. The mean duration of use was around 4 months in the US and Denmark. In
189 Canada, the mean duration of use was slightly longer, at about 8 months. Further, about 75% of
190 the affected valsartan episodes were not longer than 8 months in US and Denmark and 12
191 months in Canada. This translates to a maximum duration of exposure of 1.5% (12 months out of
192 840 months (70 years)) of the lifetime exposure for most cancer risk assessments. Our study also
193 revealed that despite availability of non-recalled valsartan products, the preference was to switch
194 to non-valsartan ARB after the recall notices were issued in July 2018.

195 Nitrosamines, NDMA and NDEA are classified as probable carcinogens for humans given the
196 limited evidence of carcinogenicity in humans but established evidence in animal studies.⁵
197 NDMA and NDEA are suspected to have both local and systemic carcinogenic potential
198 following activation to diazonium ions (methyldiazonium, ethyldiazonium).¹³ These diazonium
199 ions are precursors of reactive electrophilic carbenium ions, which directly react with DNA to
200 form stable adducts (a segment of the DNA bound to a carcinogenic chemical). Adducts that are
201 not removed by the cell can cause mutations that may give rise to cancer.¹⁴ As such it is expected
202 that chronic exposure to nitrosamines is necessary for carcinogenesis. With regards to types of
203 cancers, the EMA's ad-hoc expert group on nitrosamine impurities in human medicinal
204 products¹⁵ concluded that the liver may be the most impacted organ due to activation of
205 nitrosamines during first pass hepatic metabolism. Activated nitrosamines are very reactive and

206 are unlikely to be released into the circulation. However, many other sites, including the
207 gastrointestinal tract, are metabolically competent and can also activate nitrosamines.^{16,17} Based
208 on the duration of exposure found in our study, a marked increased risk of liver or the
209 gastrointestinal cancer from the nitrosamine impurity is unlikely. An observational study
210 conducted to examine risk of these cancers also found no increased risk for cancers with
211 valsartan products.¹⁸

212 Our study has several strengths. It is the first observational study to date to characterize the
213 extent of exposure to valsartan products with nitrosamine impurities in three countries. It covers
214 the entire period when the valsartan products with nitrosamine impurities were in circulation,
215 allowing for the complete capture of nitrosamine exposure from valsartan products described
216 within the study databases. The use of dispensing claims data means that patients filled their
217 prescriptions, though the actual ingestion of these products cannot be confirmed.

218 **LIMITATIONS**

219 Within the recalled-tested products, it was likely that all products lots for the assigned NDC were
220 affected. However, for the recalled products, only selected lots are indicated on the recalled list
221 were affected by the contamination. For recalled products, our exposure algorithm was unable to
222 identify specific affected lots. Thus, the proportion of recalled valsartan episodes may be
223 overestimated. We were also unable to identify a date when all valsartan products with
224 nitrosamine impurities were no longer on the market. To estimate exposure, we assumed that
225 valsartan products with nitrosamine impurities were no longer on market by December 2018, but
226 we acknowledge that this may not have been the case across the board. Another limitation relates
227 to potential additional contamination exposure from switching to non-valsartan ARBs that were
228 affected prior to issuance of the recall notices. It is possible that prior to the recall dates valsartan

229 users switched to other affected ARBs and could have had additional exposure to nitrosamine
230 impurities. However, we were unable to evaluate this possibility as the date of first introduction
231 of the nitrosamine impurities for the other ARBs was not well characterized at the time of the
232 analysis. Lastly, we acknowledge that there could be other sources of nitrosamine exposure from
233 water and food, which may also affect cancer risk, and these were not considered in this study.

234 **CONCLUSION**

235 Between 2012 and 2018, recalled generic valsartan products had the largest share of the valsartan
236 market in the US, Canada, and Denmark. Despite widespread use, the duration of use of recalled
237 products was relatively short and likely does not pose an elevated risk of nitrosamine-induced
238 cancer. However, since products with nitrosamine impurity could have been on the market over a
239 six-year period, patients potentially exposed to these products for longer duration could have a
240 different risk of cancer.

241 **Acknowledgments, Sources of Funding, & Disclosures**

242 **a) Acknowledgements**

243 Many thanks are due to those who participated in this project:

244 The Canadian Network for Observational Drug Effect Studies (CNODES), a collaborating center
245 of the Drug Safety and Effectiveness Network (DSEN). This study was made possible through
246 data-sharing agreements between the CNODES member research centers and the respective
247 provincial governments of Manitoba, Nova Scotia, Ontario, and Saskatchewan.

248 U.S. Data Partners who provided data used in the analysis: CVS Health (Aetna), Bell, PA;

249 Carelon Research/Elevance Health, Wilmington, DE; Duke University School of Medicine,

250 Department of Population Health Sciences, Durham, NC, through the Centers for Medicare and

251 Medicaid Services which provided data; Humana Healthcare Research Inc., Louisville, KY;
252 Northern California, Division of Research, Oakland, CA; OptumInsight Life Sciences Inc.,
253 Boston, MA; Vanderbilt University Medical Center, Department of Health Policy, Nashville,
254 TN, through the TennCare Division of the Tennessee Department of Finance & Administration
255 which provided data.

256 **b) Sources of Funding**

257 The Canadian Network for Observational Drug Effect Studies (CNODES) is a core network
258 partner of CoLab and funded by Canadian Agency for Drugs and Technologies in Health,
259 CADTH (Grant #C222 360). At the time of this study CNODES was a collaborating center of
260 the Drug Safety and Effectiveness Network (DSEN) and funded by the Canadian Institutes of
261 Health Research (CIHR; Grant # DSE-146021). This study was made possible through data
262 sharing agreements between the participating CNODES member research centers and the
263 respective provincial governments of Manitoba, Nova Scotia, Ontario, and Saskatchewan. This
264 project was supported by Task Order 75F40119F19002 under Master Agreement
265 75F40119D10037 from the U.S. Food and Drug Administration (FDA).

266 **c) Disclosures**

267 The FDA approved the study protocol including statistical analysis plan, and reviewed and
268 approved this manuscript. Authors who are employees or contractors of the U.S. Food and Drug
269 Administration, played a role in the design, results interpretation and in the preparation and
270 decision to submit the manuscript for publication; however, other officials at the U.S. Food and
271 Drug Administration, had no role in the design and conduct of the study; collection,
272 management, analysis, and interpretation of the data; and preparation, review, or approval of the
273 manuscript; and decision to submit the manuscript for publication. The Danish regulatory

274 authority and CADTH and the Canadian Institutes of Health Research had no role in the design
275 and conduct of the study; collection, management, analysis, and interpretation of the data; and
276 preparation, review, or approval of the manuscript; and decision to submit the manuscript for
277 publication.

278 **Disclaimers:** The opinions, results, and conclusions are those of the authors; no endorsement by
279 the provincial governments, data stewards, Health Canada, CADTH or CIHR is intended or
280 should be inferred. The views expressed are the authors' and not necessarily those of the U.S.
281 Food and Drug Administration, or the U.S. Department of Health and Human Services.

282

283


284 REFERENCES

- 285 1. FDA announces voluntary recall of several medicines containing valsartan following
286 detection of an impurity. 2018. Accessed May 26, 2022. [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity)
287 [announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-](https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity)
288 [following-detection-impurity](https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity)
- 289 2. EMA reviewing medicines containing valsartan from Zhejiang Huahai following
290 detection of an impurity: some valsartan medicines being recalled across the EU. 2018. Accessed
291 May 26, 2022. [https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-](https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some)
292 [valsartan-zhejiang-huahai-following-detection-impurity-some](https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some)
- 293 3. Several drugs containing valsartan being recalled due to contamination with a potential
294 carcinogen. 2018. Accessed May 26, 2022. [https://recalls-rappels.canada.ca/en/alert-](https://recalls-rappels.canada.ca/en/alert-recall/several-drugs-containing-valsartan-being-recalled-due-contamination-potential)
295 [recall/several-drugs-containing-valsartan-being-recalled-due-contamination-potential](https://recalls-rappels.canada.ca/en/alert-recall/several-drugs-containing-valsartan-being-recalled-due-contamination-potential)
- 296 4. Blood pressure and heart medication recalled from Pharmacie. 2018. Accessed May 26,
297 2022. [https://www.gov.uk/government/news/blood-pressure-and-heart-medication-recalled-](https://www.gov.uk/government/news/blood-pressure-and-heart-medication-recalled-from-pharmacies)
298 [from-pharmacies](https://www.gov.uk/government/news/blood-pressure-and-heart-medication-recalled-from-pharmacies)
- 299 5. International Agency for Research on Cancer (IARC). *IARC monographs on the*
300 *evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating*
301 *of IARC Monographs*. Vol. 1-42. 1987.
- 302 6. Eworuke E, Shinde M, Hou L, Paterson MJ, Jensen PB, Maro JC, Rai A, Scarnecchia D,
303 Pennap D, Woronow D, Ghosh RE, Welburn S, Pottegard A, Platt RW, Lee H, Bradley MC.
304 Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the
305 nitrosamine recalls: a descriptive cohort study. *BMJ Open*. 2023 Apr 17;13(4):e070985. doi:
306 10.1136/bmjopen-2022-070985.
- 307 7. US Food and Drug Administration. Laboratory analysis of valsartan products. Accessed
308 May 26, 2022, 2022. [https://www.fda.gov/drugs/drug-safety-and-availability/search-list-recalled-](https://www.fda.gov/drugs/drug-safety-and-availability/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and)
309 [angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and](https://www.fda.gov/drugs/drug-safety-and-availability/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and)
- 310 8. Government of Canada. Impurities found in certain angiotensin II receptor blocker
311 (ARB) products, also known as sartans. Accessed 12/20/2022, 2022.
312 [https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-](https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/angiotensin-receptor-blocker.html)
313 [enforcement/information-health-product/drugs/angiotensin-receptor-blocker.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/angiotensin-receptor-blocker.html)
- 314 9. Basic HHS Policy for Protection of Human Research Subjects, Title 45 FR 7259, 7273
315 1-23 (2017). [https://www.fda.gov/drugs/drug-safety-and-availability/information-about-](https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications)
316 [nitrosamine-impurities-medications](https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications)
- 317 10. Federal Policy for the Protection of Human Subjects. In: Office for Human Research
318 Protections (OHRP) DoHaHS, editor. 82 FR 71492017. p. 126.
- 319 11. Rosati K JN, Soliz M, Evans BJ. . Sentinel Initiative Principles and Policies: HIPAA and
320 Common Rule Compliance in the Sentinel Initiative. 2018.
- 321 12. Sentinel Operations Center. Common data model.
322 https://dev.sentinel-system.org/projects/SCDM/repos/sentinel_common_data_model/browse
- 323 13. Peto R, Gray R, Brantom P, Grasso P. Nitrosamine carcinogenesis in 5120 rodents:
324 chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in
325 the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting
326 (3, 6 or 20 weeks) and of species (rats, mice or hamsters). *IARC Sci Publ*. 1984;(57):627-65.

- 327 14. Portfolio N. DNA Adducts. Accessed 12/15/2022, [https://www.nature.com/subjects/dna-](https://www.nature.com/subjects/dna-adducts)
328 adducts
- 329 15. European Medicines Agency. Pharmacovigilance Risk Assessment Committee: Minutes
330 of meeting on 10-13 February 2020. 2020:82.
- 331 16. Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence,
332 formation, mechanisms and carcinogenic potential. *Mutation Research/Genetic Toxicology*.
333 1991/03/01/ 1991;259(3):277-289. doi:[https://doi.org/10.1016/0165-1218\(91\)90123-4](https://doi.org/10.1016/0165-1218(91)90123-4)
- 334 17. Bartsch H, O'Neill IK. Ninth International Meeting on N-Nitroso Compounds:
335 Exposures, Mechanisms, and Relevance to Human Cancer1. *Cancer Research*.
336 1988;48(16):4711-4714.
- 337 18. Pottegård A, Christensen Rd, Houji A, et al. Primary non-adherence in general practice: a
338 Danish register study. *European Journal of Clinical Pharmacology*. 2014/06/01 2014;70(6):757-
339 763. doi:10.1007/s00228-014-1677-y


340

341




342
343
344
345
346
347
348

Figure 1. Trends in valsartan utilization stratified by nitrosamine impurity status in the US. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020). For recalled products, use after 2019 reflects production without nitrosamine impurities.



349
350
351
352
353
354
355

Figure 2. Trends in valsartan utilization stratified by nitrosamine impurity status in Canada. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020). For recalled products, use after 2019 reflects production without nitrosamine impurities.



356
357
358
359
360
361

Figure 3 Trends in valsartan utilization stratified by nitrosamine impurity status in Denmark. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020).

362 Table 1. Characteristics of valsartan users, stratified by valsartan nitrosamine-impurity status for US, Canada, and Denmark between
 363 May 1, 2012, through December 31, 2020,

Characteristics	US (N=7,925,941 total episodes)				Canada (N=442,189 total episodes)				Denmark* (N=16,260 total episodes)		
	Recalled- tested products (N, %)	Recalled products (N, %)	Non- recalled Generic products (N, %)	Non- recalled Branded products (N, %)	Recalled -tested products (N, %)	Recalled products (N, %)	Non- recalled Generic products (N, %)	Non- recalled Branded products (N, %)	Recalled products (N, %)	Non- recalled Generic products (N, %)	Non-recalled Branded products (N, %)
Number of episodes	3,299,942 (41.6)	2,826,914 (35.7)	3,285,556 (41.5)	3,167,728 (40.0)	51,315 (11.6)	291,229 (65.9)	35,973 (8.1)	215,999 (48.8)	10,747 (66.1)	9,395 (57.8)	7,632 (46.9)
Number of unique patients	2,042,708	1,683,995	1,972,104	1,884,770	34,893	156,933	26,105	114,546	4,020	3,361	4,707
Demographics											
Age [†] , %											
18-44	3.7	3.9	3.7	4.5	2.1	2.7	2.2	2.2	3.4	3.2	3.0
45-64	25.0	25.7	24.1	26.0	16.9	17.7	15.2	17.1	38.1	35.4	31.2
>65	71.3	70.4	72.2	69.5	81.0	79.6	82.6	80.6	58.5	61.5	65.7
Sex, %											
Female	57.1	56.8	56.9	54.2	56.2	57.2	57.4	51.3	51.8	52.0	35.6
Male	42.9	43.2	43.1	45.8	43.8	42.8	42.6	48.7	48.2	48.0	64.4

364 *In Denmark, due to the inability to access testing data, the recalled products were not further categorized into recalled-tested and recalled
 365 products.

366 [†]Age at index date (first valsartan dispensing)

367

368

369

370 Table 2. Summary statistics for the duration of valsartan episodes between May 1, 2012, and December 31, 2018*, by valsartan
 371 nitrosamine-impurity status

Valsartan Category	US						Canada						Denmark					
	Total episodes (N)	Mean (days)	St. Dev (days)	Median (days)	25th Percentile (days)	75th Percentile	Total episodes (N)	Mean (days)	St. Dev (days)	Median (days)	25th Percentile (days)	75th Percentile (days)	Total episodes (N)	Mean (days)	St. Dev (days)	Median (days)	25th Percentile (days)	75th Percentile (days)
Recalled-tested	2,516,120	166.9	223.1	29-93	2-32	60-222	36786	145.4	255.8	48-69	4-9	139-192	10,551	166.2	251.0	99	30	181
Recalled	2,265,238	178.3	249.6	28-95	2-35	60-230	26735	269.0	397.3	104-121	22-50	315-407						
Non-recalled generic	2,020,032	164.7	231.4	20-93	1-32	60-213	23106	146.7	230.9	61-85.5	5-11	174-255.5	8108	136.8	194.0	90	28	142
Non-recalled branded	2,639,380	167.7	228.0	60-100	5-53	96-219	15786	319.2	489.1	98-120	16-25	356-400	4708	321.6	376.2	154	58	497.5

372 Mean duration in US and Canada databases is an average of the episode duration across all data partners. Median, 25th and 75th
 373 percentiles are the lowest and highest value reported across the data partners.

374
 375 * period valsartan products with NDMA/NDEA impurity were assumed to have been available

